Treating cancer-related hypercalcemia with gallium nitrate

Journal of Supportive Oncology

Volumn 2, Issue 6, 2004, Pages 509-516

  Leyland Jones, Brian ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DIURETIC AGENT; ETIDRONIC ACID; GALLIUM NITRATE; MITHRAMYCIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PHOSPHORUS; PLACEBO; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ANEMIA; ANTINEOPLASTIC ACTIVITY; BICARBONATE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE RESISTANCE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EPIDERMOID TUMOR; FATALITY; FLUID THERAPY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; KIDNEY FUNCTION; MORBIDITY; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; OSSIFICATION; OSTEOLYSIS; PATHOGENESIS; QUALITY OF LIFE; REHYDRATION; REVIEW; SIDE EFFECT; TACHYPHYLAXIS; TINNITUS;

DRUG ADMINISTRATION SCHEDULE; GALLIUM; HUMANS; HYPERCALCEMIA; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX;

EID: 11944268322     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Lang-Kummer J. Hypercalcemia. In: Groenwald SL, Frogge MH, Goodman M, Yarbro CH, eds. Cancer Nursing. Principles and Practice. 4th ed. Sudbury, Mass: Jones and Bartlett Publishers; 1997:684-701.
2. Muggia FM. Overview of cancer-related hypercalcemia: epidemiology and etiology. Semin Oncol 1990;17(2 suppl 5):3-9.
3. National Cancer Institute. Hypercalcemia (PDQ®). Available at: http://www.cancer.gov/cancerinfo/pdq/supportivecare/hypercalcemia/ HealthProfessional. Accessed March 16, 2004.
4. Warrell RP Jr. Metabolic emergencies. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams and Wilkins; 2001:2633-2645.
5. National Comprehensive Cancer Network. Palliative Care. Clinical Practice Guidelines in Oncology -v.1.2003. Available at: http://www.nccn.org/professionals/physician_gls/PDF/palliative.pdf. Accessed March 19, 2004.
6. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54.
7. Burtis WJ, Brady TG, Orloff JJ, et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990;322:1106-1112.
8. Lamy O, Jenzer-Closuit A, Burckhard TP. Hypercalcaemia of malignancy: an undiagnosed and undertreated disease. J Intern Med 2001;250:73-79.
9. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567.
10. Warrell RP Jr, Coonley CJ, Straus DJ, Young CW. Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 1983;51:1982-1987.
11. Warrell RP Jr, Bockman RS, Coonley CJ, Isaacs M, Staszewski H. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 1984;73:1487-1490.
12. Bockman RS. Studies on the mechanism of action of gallium nitrate. Semin Oncol 1991;18(4 suppl 5):21-25.
13. Bockman RS, Boskey AL, Blumenthal NC, Alcock NW, Warrell RP Jr. Gallium increases bonecalcium and crystallite perfection of hydroxyapatite. Calcif Tissue Int 1986;39:376-381.
14. Bockman RS, Repo MA, Warrell RP Jr, et al. Distribution of trace levels of therapeutic gallium in bone as mapped by synchrotron x-ray microscopy. Proc Natl Acad Sci U S A 1990;87:4149-4153.
15. Repo MA, Bockman RS, Betts F, et al. Effect of gallium on bone mineral properties. Calcif Tissue Int 1988;43:300-306.
16. Blair HC,T eitelbaum SL, Tan HL, Schlesinger PH. Reversible inhibition of osteoclastic activity by bone-bound gallium (III). J Cell Biochem 1992;48:401-410.
17. Donnelly R, Bockman RS, Doty SB, Boskey AL. Bone particles from gallium-treated rats are resistant to resorption in vivo. Bone Miner 1991;12:167-179.
18. Hall TJ, Chambers TJ. Gallium inhibits bone resorption by a direct effect on osteoclasts. Bone Miner 1990;8:211-216.
19. Stern LS, Matkovic V, Weisbrode SE, et al. The effects of gallium nitrate on osteopenia induced by ovariectomy and a low-calcium diet in rats. Bone Miner 1994;25:59-69.
20. Blumenthal NC, Cosma V, Levine S. Effect of gallium on the in vitro formation, growth, and solubility of hydroxyapatite. Calcif Tissue Int 1989;45:81-87.
21. Donnelly R, Boskey A. The effect of gallium on seeded hydroxyapatite growth. Calcif Tissue Int 1989;44:138-142.
22. Schlesinger PH, Blair HC. Mechanism of osteoclast inhibition by group IIIa metals; pH dependent release from the bone surface causes direct V-H+-ATPase inhibition without general metabolic inhibition [abstract]. J Bone Miner Res 1999;14(suppl 1):S414.
23. Schlesinger PH, Teitelbaum SL, Blair HC. Osteoclast inhibition byGa3+ contrasts with bisphosphonate metabolic suppression: competitive inhibition of H+ ATPase by bone-bound gallium [abstract]. J Bone Miner Res 1991;6:S127.
24. Bernstein LR. Mechanisms of therapeutic activity for gallium. Pharmacol Rev 1998;50:665-682.
25. Warrell RP Jr, Skelos A, Alcock NW, Bockman RS. Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis. Cancer Res 1986;46:4208-4212.
26. Warrell RP Jr, Israel R, Frisone M, et al. Gallium nitrate for acute treatment of cancer-related hypercalcemia: a randomized, double-blind comparison to calcitonin. Ann Intern Med 1988;108:669-674.
27. Warrell RP Jr, Murphy WK, Schulman P, O'Dwyer PJ, Heller G. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 1991;9:1467-1475.
28. Bertheault-Cvitkovic F, Armand JP, Tubiana-Hulin M, et al. Randomized, double blind comparison of pamidronate vs. gallium nitrate for acute control of cancer related hypercalcemia. In: Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy; March 12-15, 1996; Amsterdam, The Netherlands. Abstract 140.
29. Budayr AA, Nissenson RA, Klein RF, et al. Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann Intern Med 1989;111:807-812.
30. Henderson JE, Shustik C, Kremer R, et al. Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism. J Bone Miner Res 1990;5:105-113.
31. Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calicif Tissue Int 1990;46:S26-S30.
32. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993;341:1611-1613.
33. Walls J, Ratcliffe WA, Howell A, Bundred NJ. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 1994;70:169-172.
34. Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994;73:2223-2230.